Rituximab may be clinically valuable as initial therapy for HIV-associated multicentric Castleman disease.
No takes yet. Share an insight, caveat, or question.
Bower et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: